Teva Pharmaceutical Industries Ltd.
) recently entered into an agreement with
Champions Oncology Inc.
) for the development of advanced technology solutions and
services so that the evaluation and use of oncology drugs can be
Champions Oncology's TumorGraft technology platform will be
used to improve and speed up the development of several of Teva's
Under the partnership, the TumorGraft technology platform will
be used to identify highly responsive cancer subtypes and their
corresponding molecular and biochemical biomarkers of
responsiveness to Teva's novel therapeutic agents. The ultimate
target is to develop new and personalized therapeutic options for
Champions Oncology is entitled to an upfront payment from Teva
as well as milestone payments. Teva will pay royalties as
Teva has signed another oncology deal, this one with the
technology development arm of Cancer Research UK's - Cancer
Research Technology Ltd. (CRT). The multi-project alliance is
aimed at the research and development of first-in-class cancer
drugs that modulate DNA damage and repair response (DDR)
processes in cancer cells.
We note that Teva has been working on strengthening its
oncology portfolio. The lead product in the company's oncology
product portfolio is Treanda. Treanda, which became a part of
Teva's portfolio following its acquisition of Cephalon, posted
sales of $608 million in 2012.
Teva currently carries a Zacks Rank #3 (Hold). The company is
going through a tough transition period given fewer large generic
opportunities, potential new competition for branded products
(especially Copaxone) and a higher cost base.
However, we are encouraged by Teva's plans to improve its
position. Teva said that it intends to accelerate growth
platforms, protect and expand core franchises, expand its global
presence, pursue strategic deals and reduce the cost base. We
expect investor focus to remain on the execution of the company's
At present, companies like
) look well-positioned with both being Zacks Rank #2 (Buy)
ACTAVIS INC (ACT): Free Stock Analysis Report
AKORN INC (AKRX): Free Stock Analysis Report
CHAMPIONS ONCLG (CSBR): Get Free Report
TEVA PHARM ADR (TEVA): Free Stock Analysis
To read this article on Zacks.com click here.